Enjoy complimentary customisation on priority with our Enterprise License!
The plasma protease C inhibitor market size is forecast to increase by USD 2.00 billion at a CAGR of 7.55% between 2023 and 2028. The market is witnessing significant growth due to the increasing research and development in this area. The complex and high cost treatment of plasma protease C1 inhibitor is driving the market's expansion. One of the notable trends in the market is the growing adoption of bradykinin B2 receptor antagonists, which are effective in inhibiting the activity of plasma protease C1. These antagonists offer a potential solution to the challenges posed by the high cost and complex treatment of plasma protease C1 inhibitor. The market is expected to continue its growth trajectory, as new treatments and therapies are being developed to address the unmet needs in this area. Overall, the market holds immense potential for growth, driven by the increasing demand for effective treatments for various diseases and conditions associated with this protein.
Plasma protease C1 inhibitor is an essential anti-inflammatory protein that plays a crucial role in regulating various systems involved in inflammation and coagulation. It inhibits the activation of the complement system and contact system, preventing the formation of inflammatory complexes. In inflammatory diseases such as sepsis and septic shock, the deficiency of C1 inhibitor can lead to uncontrolled inflammation and coagulation, resulting in severe symptoms like edema in subcutaneous tissue, gastrointestinal mucosa, and upper respiratory tract. C1 inhibitor is a member of the serpin family, which includes other protease inhibitors like antithrombin and alpha-1-antitrypsin. It inhibits proteases like plasmin, thrombin, and other enzymes involved in the classical pathway, coagulation system, kinin system, and fibrinolytic system.
Moreover, the replacement therapy is an essential treatment for individuals with C1 inhibitor deficiency, which can be caused by hereditary or acquired conditions. Symptom-free periods are crucial for patients to maintain their quality of life, making regular monitoring and kinetic follow-up essential. Plasma protease C1 inhibitor is available for purchase through various channels, including e-commerce platforms, toy sectors, and kidult markets, offering multi-brand games, second-hand toys, toy rental, and collectibles. These platforms provide convenience and accessibility to patients, ensuring they receive their necessary treatments promptly.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The hospital pharmacy segment is estimated to witness significant growth during the forecast period. The market holds immense significance due to its role in the treatment of inflammatory diseases, particularly hereditary angioedema (HAE) and acquired angioedema. This anti-inflammatory protein plays a pivotal role in regulating the complement system, contact system, and the coagulation, kinin, and fibrinolytic systems. The deficiency of C1-INH, a key component of the protease inhibition system, leads to the activation of the complement system and subsequent angioedema symptoms, including swelling of the subcutaneous tissue, gastrointestinal mucosa, and upper respiratory tract. Hospital pharmacies occupy a substantial position in the market, serving as critical intermediaries in procuring, storing, and dispensing this vital medication.
Moreover, the increasing incidence of hereditary and acquired angioedema worldwide fuels the growth of the hospital pharmacy segment. Patients with C1-INH deficiency require regular replacement therapy during symptom-free periods and during HAE attacks. Plasma protease C1 inhibitors, such as antiplasmin agents, help prevent the activation of thrombin and the formation of complexes, thereby mitigating the symptoms of angioedema. Moreover, hospital pharmacies ensure the accessibility and availability of these life-saving medications for patients, making them indispensable in the healthcare ecosystem. The e-commerce sector, including toy rental, multi-brand games, and second-hand toys, may also emerge as potential growth avenues for the market, as the demand for these products among kids (kidults) continues to rise. The pathogenesis of angioedema involves the activation of various plasma enzyme systems, including serine protease inhibitors, making Plasma Protease C1 Inhibitor a crucial intervention in managing this condition.
Get a glance at the market share of various segments Request Free Sample
The hospital pharmacy segment was valued at USD 1.78 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market is witnessing significant growth due to the increasing number of blood samples being taken for diagnostic purposes and the subsequent rise in plasma concentrations of C1 inhibitor being measured. The molecular background of Hereditary Angioedema (HAE), a rare and potentially life-threatening condition characterized by recurrent episodes of edema, is driving the demand for effective treatment options. In North America, the well-established healthcare infrastructure and the presence of prominent market participants are catalyzing market growth. Organizations such as the US Hereditary Angioedema Association are raising awareness about HAE treatment and offering support to patients. A recent study published in the National Library of Medicine evaluated the impact of new treatment options on physician practice patterns, further emphasizing the importance of continuous research and development in this field.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing research and development in plasma protease C1 inhibitors is the key driver of the market. The market is projected to experience significant growth due to the increasing focus of biopharmaceutical firms on developing effective treatments for inflammatory diseases, particularly hereditary angioedema (HAE) and acquired angioedema. The complement system and contact system play crucial roles in the pathogenesis of angioedema, which involves protease activation and the subsequent release of inflammatory mediators. Plasma protease C1 inhibitor, an anti-inflammatory protein, plays a key role in regulating the complement and coagulation systems, as well as the kinin and fibrinolytic systems. Deficiency in this protein leads to C1-INH deficiency, resulting in symptoms such as swelling of the subcutaneous tissue, gastrointestinal mucosa, and upper respiratory tract during HAE attacks.
Moreover, currently, replacement therapy using plasma-derived or recombinant C1-INH is the standard treatment for HAE. However, the development of oral, on-demand therapies like KVD900, being evaluated in the Phase 3 KONFIDENT Clinical Trial by KalVista Pharmaceuticals, Inc., holds promise for improving patient convenience and outcomes. Serine protease inhibitors, including antiplasmin agents, are also being explored as potential treatments for various disorders involving protease imbalance. The global market for plasma protease C1 inhibitor is expected to witness substantial growth due to the increasing demand for effective treatments for angioedema and other inflammatory conditions.
Growing adoption of bradykinin B2 receptor antagonists is the upcoming trend in the market. Plasma protease C1 inhibitors serve a vital function as regulatory proteins in the inhibition of the complement and contact systems, specifically in the prevention of bradykinin production. Bradykinin, an inflammatory mediator, is implicated in various pathological conditions, most notably angioedema. In disorders such as hereditary angioedema (HAE) and acquired angioedema, insufficient levels of plasma protease C1 inhibitors lead to uncontrolled bradykinin release, triggering angioedema symptoms in the subcutaneous tissue, gastrointestinal mucosa, and upper respiratory tract. To combat this issue, Bradykinin B2 receptor antagonists have emerged as a promising therapeutic solution. These agents inhibit the activation of B2 receptors by bradykinin, thereby mitigating angioedema symptoms and preventing future attacks.
Moreover, the global market is witnessing significant growth due to the increasing adoption of Bradykinin B2 receptor antagonists, which offer effective management of HAE attacks and symptom-free periods. The complement system, contact system, coagulation system, and fibrinolytic system are all impacted by protease inhibition, and deficiencies in C1-INH can lead to complexes with thrombin, resulting in HAE attacks. Serine protease inhibitors and plasma enzyme systems play essential roles in the pathogenesis of angioedema. The market for these therapies is expected to grow further due to the increasing prevalence of angioedema and the availability of replacement therapies, antiplasmin agents, and various e-commerce platforms for purchasing medications, as well as the expansion of multi-brand games, toys, and toy rentals, including brands like Lego and Playmobil.
The high cost and complex treatment of plasma protease C1 inhibitor is a key challenge affecting the market growth. Plasma protease C1 inhibitor plays a crucial role in the regulation of the complement and contact systems, acting as an essential anti-inflammatory protein in the body. Deficiencies in this protein can lead to inflammatory diseases such as hereditary angioedema (HAE) and acquired angioedema. In HAE, C1-INH deficiency results in the activation of the complement system, coagulation system, kinin system, and fibrinolytic system, leading to angioedema symptoms such as swelling in the subcutaneous tissue, gastrointestinal mucosa, and upper respiratory tract. Current treatments for angioedema include replacement therapy with plasma-derived C1-INH or recombinant C1-INH. However, these treatments come with challenges such as infection risk, treatment resistance, low compliance, and side effects.
However, the plasma-based medicines carry an increased risk of blood-borne diseases like HIV, hepatitis B, and hepatitis C transmission. Although primary blood screening is performed, the risk of infection transmission during transfusion remains significant due to various pathogen strains, blood purification-resistant pathogens, and the threat of new viruses such as flaviviruses. Serine protease inhibitors, such as antiplasmin agents, are alternative treatments for managing angioedema symptoms. These inhibitors target specific proteases involved in the pathogenesis of angioedema, reducing the need for plasma-derived products. The e-commerce sector, including toy rental, multi-brand games, and second-hand toys, may offer accessible and cost-effective alternatives for individuals with angioedema, allowing them to enjoy activities during symptom-free periods without the risk of exposure to C1-INH deficiency-triggering factors.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers a crucial treatment option for patients diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and life-threatening blood disorder.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is driven by the increasing prevalence of inflammatory diseases, particularly those involving the complement system and contact systems. The complement system and contact system are integral parts of the immune response, and their dysregulation can lead to various inflammatory conditions. Plasma protease C1 inhibitor is an essential anti-inflammatory protein that plays a crucial role in the regulation of these systems by inhibiting the activation of C1, the first component of the classical pathway, and plasmin, a key enzyme in the coagulation, fibrinolytic, and kinin systems. Deficiencies in plasma protease C1 inhibitor can result in hereditary angioedema (HAE) and acquired angioedema (AAE), characterized by swelling of the subcutaneous tissue, gastrointestinal mucosa, and upper respiratory tract.
Moreover, these symptoms can be life-threatening in some cases. Replacement therapy using plasma-derived or recombinant C1 inhibitors is an effective treatment for managing HAE and AAE. Serine protease inhibitors, including C1 inhibitors, are essential components of plasma enzyme systems. The pathogenesis of angioedema involves the activation of various plasma enzymes, including thrombin, which form complexes with C1 inhibitors during symptom-free periods. These complexes can contribute to the development of HAE and AAE during hemostatic challenges. The market for plasma protease C1 inhibitors is expected to grow due to the increasing demand for effective treatments for inflammatory diseases and the expanding application of these inhibitors in various therapeutic areas.
Furthermore, the e-commerce sector, including sales of toys and games, is also expected to contribute to the growth of the market. For instance, multi-brand games, such as Lego and Playmobil, and construction toys, can potentially trigger angioedema symptoms in children with C1-inhibitor deficiency. The availability of these toys online and the increasing popularity of toy rental services and second-hand toys may increase the risk of exposure to potential triggers for angioedema.
Market Scope |
|
Report Coverage |
Details |
Page number |
166 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.55% |
Market growth 2024-2028 |
USD 2.00 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.12 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bio Techne Corp., BioCryst Pharmaceuticals Inc., Biosynth Ltd., Bristol Myers Squibb Co., Cayman Chemical, CSL Ltd., FibroGen Inc., Fresenius SE and Co. KGaA, Gilead Sciences Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Merck KGaA, Novartis AG, Pharming Group NV, Sino Biological Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.